Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Identifying combinations of repurposed drugs for new treatments of acute myeloid leukaemia
Facing the MuSIC - identification of synergistic repurposed drug combinations as novel therapies in paediatric acute myeloid leukaemia
Understanding why some children with neuroblastoma have worse survival or respond badly to treatment
Targeting the Fanconi Anaemia pathyway in neuroblastoma
Improving our understanding of brain tumours in teenagers and young adults
Teenagers and young adults with primary CNS cancers: a systematic biological characterisation
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics
Using the immune system to improve treatment for Hodgkin lymphoma
Targeting GPNMB in Hodgkin lymphoma
Finding new drugs to treat high-risk rhabdomyosarcoma
High-risk rhabdomyosarcoma patient derived 3D cultures to screen for novel drugs that enhance sensitivity to standard treatment
Understanding the molecular makeup of low grade glioma and DIPG
Molecular pathophysiology of histone G34R mutated childhood brain tumours: towards the development of novel targeted therapies
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies